Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients

Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial of Principle (TOP) study, in which patients with estrogen receptor (ER)–negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically de...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Genom Data
Autors principals: Haibe-Kains, B., Desmedt, C., Di Leo, A., Azambuja, E., Larsimont, D., Selleslags, J., Delaloge, S., Duhem, C., Kains, J.P., Carly, B., Maerevoet, M., Vindevoghel, A., Rouas, G., Lallemand, F., Durbecq, V., Cardoso, F., Salgado, R., Rovere, R., Bontempi, G., Michiels, S., Buyse, M., Nogaret, J.M., Qi, Y., Symmans, F., Pusztai, L., D'Hondt, V., Piccart-Gebhart, M., Sotiriou, C.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2013
Matèries:
Data in Brief
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4608867/
https://ncbi.nlm.nih.gov/pubmed/26484051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gdata.2013.09.001
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars